Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...
A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...
(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...
What innovative approaches in imaging are you seeing advancing immuno-oncology? Two innovations stand out, and they are not mutually exclusive. Molecular imaging, such as PET, utilizes specific ...
Mutation profiling of appendiceal cancer: Distinguishing tumor grades, comprehensive mutation landscape, and ctDNA as a discovery tool. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Extrachromosomal DNAs (ecDNAs) are circular DNA structures located in the nuclei of cells outside chromosomes. They were originally discovered in chromosome spreads of cells obtained from embryonal ...
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results